Rigel Pharmaceuticals, Inc.
1180 Veterans Boulevard
South San Francisco
California
94080
U.S.A.
Phone:
650-624-1100
Fax:
650-624-1101
|
Rigel's. Rigel's mission is to become a source of novel, small-molecule drugs to address large, unmet medical needs. We have initiated four development programs: asthma/allergy, hepatitis C, rheumatoid arthritis and oncology. Our first two product candidates, R112 for allergic rhinitis and R803 for hepatitis C, are in clinical testing. We expect to begin a clinical trial of R406 for the treatment of rheumatoid arthritis by the end of 2004, to be followed by initiation of clinical trials with additional product candidates for indications in oncology and asthma. Our approach to drug discovery is based on advanced, proprietary techniques that allow us to identify targets with a demonstrable role in a disease pathway and to screen efficiently for those targets that are likely to be amenable to drug modulation. We believe that this approach to drug discovery will enable us to commence clinical trials with one to two lead compounds each year. Our research efforts are focused in the areas of immunology/inflammation, virology and oncology.
Last Updated: 10-18-04
Email:
communications@rigel.com
Ownership:
Public
Web Site:
Rigel Pharmaceuticals, Inc.
Employees:
135
Symbol: RIGL
|